665 related articles for article (PubMed ID: 27637305)
21. Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation.
Deitelzweig S
Cardiovasc Ther; 2014 Apr; 32(2):74-81. PubMed ID: 24119252
[TBL] [Abstract][Full Text] [Related]
22. Antidotes to non-vitamin K oral anticoagulants: necessary or not?
Proietti M; Lip GY
Expert Opin Pharmacother; 2015; 16(11):1573-6. PubMed ID: 26077323
[TBL] [Abstract][Full Text] [Related]
23. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
[TBL] [Abstract][Full Text] [Related]
24. Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation.
Bisson A; Angoulvant D; Philippart R; Clementy N; Babuty D; Fauchier L
Adv Ther; 2017 Jun; 34(6):1283-1290. PubMed ID: 28493056
[TBL] [Abstract][Full Text] [Related]
25. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
[TBL] [Abstract][Full Text] [Related]
26. Anticoagulant prevention in patients with atrial fibrillation: alternatives to vitamin K antagonists.
Kozlowski D; Budrejko S; Raczak G; Rysz J; Banach M
Curr Pharm Des; 2013; 19(21):3816-26. PubMed ID: 23286429
[TBL] [Abstract][Full Text] [Related]
27. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
[TBL] [Abstract][Full Text] [Related]
28. Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in 'real-world' atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients.
Esteve-Pastor MA; Rivera-Caravaca JM; Roldán V; Vicente V; Romiti GF; Romanazzi I; Proietti M; Valdés M; Marín F; Lip GYH
Int J Cardiol; 2018 Mar; 254():125-131. PubMed ID: 29248163
[TBL] [Abstract][Full Text] [Related]
29. Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants.
Pastori D; Lip GYH; Farcomeni A; Del Sole F; Sciacqua A; Perticone F; Marcucci R; Grifoni E; Pignatelli P; Violi F;
Int J Cardiol; 2018 Aug; 264():58-63. PubMed ID: 29776574
[TBL] [Abstract][Full Text] [Related]
30. Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke.
Diener HC; Ntaios G; O'Donnell M; Easton JD
Expert Opin Pharmacother; 2018 Oct; 19(14):1597-1602. PubMed ID: 30152249
[TBL] [Abstract][Full Text] [Related]
31. Comparing the risk of dementia in subjects with atrial fibrillation using non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists: a Belgian nationwide cohort study.
Grymonprez M; Petrovic M; De Backer TL; Ikram MA; Steurbaut S; Lahousse L
Age Ageing; 2023 Mar; 52(3):. PubMed ID: 36934339
[TBL] [Abstract][Full Text] [Related]
32. Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.
Konieczyńska M; Sobieraj E; Bryk AH; Dębski M; Polak M; Podolec P; Małecka B; Pająk A; Desteghe L; Heidbuchel H; Undas A
Kardiol Pol; 2018; 76(7):1089-1096. PubMed ID: 29528483
[TBL] [Abstract][Full Text] [Related]
33. Fitting the right non-vitamin K antagonist oral anticoagulant to the right patient with non-valvular atrial fibrillation: an evidence-based choice.
Li YG; Pastori D; Lip GYH
Ann Med; 2018 Jun; 50(4):288-302. PubMed ID: 29608110
[TBL] [Abstract][Full Text] [Related]
34. Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients.
Dillinger JG; Aleil B; Cheggour S; Benhamou Y; Béjot Y; Marechaux S; Delluc A; Bertoletti L; Lellouche N
Arch Cardiovasc Dis; 2018 Feb; 111(2):85-94. PubMed ID: 28988597
[TBL] [Abstract][Full Text] [Related]
35. New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons.
Hirschl M; Kundi M
Vasa; 2014 Sep; 43(5):353-64. PubMed ID: 25147012
[TBL] [Abstract][Full Text] [Related]
36. [Procedures on patients receiving NOACs : What's possible?].
Polzin A; Kelm M; Horn P
Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):117-124. PubMed ID: 28074294
[TBL] [Abstract][Full Text] [Related]
37. Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants.
Morais J; De Caterina R
Cardiovasc Drugs Ther; 2016 Apr; 30(2):201-14. PubMed ID: 26780749
[TBL] [Abstract][Full Text] [Related]
38. Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding.
Gremmel T; Niessner A; Domanovits H; Frossard M; Sengölge G; Steinlechner B; Sycha T; Wolzt M; Pabinger I
Wien Klin Wochenschr; 2018 Dec; 130(23-24):722-734. PubMed ID: 30128955
[TBL] [Abstract][Full Text] [Related]
39. Non-Vitamin K Antagonist Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients With Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials.
Kumar S; Danik SB; Altman RK; Barrett CD; Lip GY; Chatterjee S; Roubin GS; Natale A; Danik JS
Cardiol Rev; 2016; 24(5):218-23. PubMed ID: 26274538
[TBL] [Abstract][Full Text] [Related]
40. Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial.
Joosten LPT; van Doorn S; Hoes AW; Nierman MC; Wiersma NM; Koek HL; Hemels MEW; Huisman MV; Roes KC; van den Bor RM; Buding WF; Rutten FH; Geersing GJ
BMJ Open; 2019 Dec; 9(12):e032488. PubMed ID: 31888928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
